Evaluation of Long-Term Safety and Efficacy of Baricitinib in Pediatric Patients with Juvenile Idiopathic Arthritis: A Phase 3 Multicenter Study

The primary objective of this Phase 3 multicenter study is to evaluate the long-term **safety** and **efficacy** of **baricitinib** in patients aged 1 to less than 18 years with **Juvenile Idiopathic Arthritis** (JIA). This objective is clinically relevant as it aims to determine the therapeutic potential and safety profile of baricitinib, which could provide a new treatment option for managing JIA in pediatric patients. The study focuses on assessing the impact of baricitinib on disease activity and progression, which is crucial for improving patient outcomes and quality of life in this population.

The clinical trial involves a total of **101 participants** diagnosed with **Juvenile Idiopathic Arthritis**. The study population comprises both male and female subjects, ranging in age from 1 to 17 years. Participants were selected based on their completion of a previous study involving the drug baricitinib, and they must not have developed an allergy to the medication. The trial includes a vulnerable population, given the young age of the participants. The general health status of the participants is not specified, nor are any specific lifestyle considerations such as diet or physical activity. The selection criteria ensure that the study focuses on individuals who have prior experience with the treatment under investigation.

The clinical trial is designed to evaluate the long-term safety and efficacy of **baricitinib** in patients aged 1 to less than 18 years with **Juvenile Idiopathic Arthritis**. This is a Phase 3, multicenter study employing a randomized, double-blind, controlled trial design. The trial is expected to run from October 24, 2019, to December 18, 2030, with a maximum treatment period of 264 weeks for each participant. Participants will be administered baricitinib in either oral suspension or tablet form, with a maximum daily dose of 4 mg and a total dose not exceeding 7392 mg over the treatment period.

The sequence of study visits includes an initial screening visit to confirm eligibility, followed by regular follow-up visits to monitor safety and efficacy. The inclusion criteria require participants to have completed a previous study of baricitinib for the treatment of Juvenile Idiopathic Arthritis and to have no known allergy to the drug. The primary endpoints of the study are the number of participants experiencing one or more serious adverse events (SAEs) and the number of participants with permanent discontinuations of the investigational product.

Participants are expected to be involved in the study for the entire duration of the treatment period unless conditions arise that necessitate early termination. Such conditions may include the development of significant adverse reactions or non-compliance with study protocols. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to evaluate the long-term effects of the treatment. The study aims to provide comprehensive data on the safety and efficacy of baricitinib in the pediatric population with Juvenile Idiopathic Arthritis.

The clinical trial involves the administration of **Baricitinib**, an experimental medication, in various pharmaceutical forms. The primary formulation used is an **oral suspension**, specifically designed as a pediatric formulation. The maximum daily dose for this formulation is 4 mg, with a total maximum dose of 7392 mg over a treatment period of 264 days. The route of administration is oral, and the suspension is intended for use in patients aged 1 to 17 years with **Juvenile Idiopathic Arthritis**. The suspension is manufactured by Eli Lilly and Company Limited, and the active substance, baricitinib, is of chemical origin.

In addition to the oral suspension, **Baricitinib** is also administered in the form of a **tablet**. This formulation is not specifically pediatric and is also administered orally. The dosing regimen for the tablet form mirrors that of the oral suspension, with a maximum daily dose of 4 mg and a total maximum dose of 7392 mg over the same treatment period. The tablets are manufactured with the commercial drug substance baricitinib, and while they are packaged for clinical trial use, they do not feature commercial debossing. The tablets are also produced by Eli Lilly and Company Limited, ensuring consistency in the active substance across formulations.

Furthermore, a **film-coated tablet** form of **Baricitinib** is utilized as a comparator treatment within the study. This formulation is also administered orally, with the same dosing parameters as the other forms. The film-coated tablets are manufactured for clinical trial use, with potential variations in facilities, specifications, methods, shelf-life, and packaging compared to commercial products. Despite these differences, the film-coated tablets remain suitable for clinical trial purposes. The active substance in this formulation is also baricitinib, maintaining chemical consistency across all forms used in the trial.

Throughout the study, participant compliance with the dosing schedule is monitored to ensure adherence to the prescribed regimen. The trial aims to evaluate the long-term safety and efficacy of baricitinib in treating Juvenile Idiopathic Arthritis, with no additional non-experimental treatments, such as placebo or standard-of-care therapy, being employed in this study.

The efficacy of **Baricitinib** in the treatment of Juvenile Idiopathic Arthritis (JIA) will be assessed in a Phase 3 multicenter study. The primary endpoints for evaluating efficacy include the number of participants with one or more serious adverse events (SAEs) and the number of participants with permanent investigational product discontinuations. These endpoints will be measured throughout the study duration, which is estimated to conclude by December 18, 2030. The study will involve participants aged 1 to 17 years who have completed a previous study of **Baricitinib** and have not developed an allergy to the drug. The trial aims to confirm the long-term safety and efficacy of **Baricitinib** in this patient population.